Spotlight on Anti-CD25: Daclizumab in MS

International MS Journal

Volumn 15, Issue 3, 2008, Pages 94-98

  Schippling, Sven ^a   Martin, Roland ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Anti CD25 treatment; Antibodies; Dacuzumab; Multiple sclerosis

Indexed keywords

AMINOTRANSFERASE; AUTOANTIBODY; BETA INTERFERON; BILIRUBIN; DACLIZUMAB; INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; PLACEBO; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADD ON THERAPY; AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; BILIRUBIN BLOOD LEVEL; BREAST TENDERNESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEPRESSION; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IRON DEFICIENCY; KIDNEY ALLOGRAFT REJECTION; LIGAND BINDING; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MONOTHERAPY; MOUTH ULCER; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOSENSITIVITY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SIDE EFFECT; SKIN TOXICITY; T LYMPHOCYTE; TREATMENT DURATION; URINARY TRACT INFECTION; DRUG ANTAGONISM;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 56149086005     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
2. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353: 369-374.
3. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924-933.
4. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG Multiple sclerosis. N Engl J Med 2000; 343: 938-952.
5. Waldmann TA, Longo DL, Leonard WJ, et al. Interleukin 2 receptor (Tac antigen) expression in HTLV-I-associated adult T-cell leukemia. Cancer Res 1985; 45: 4559s-4562s.
6. Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplant Proc 1991; 23: 1066-1067.
7. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: metaanalysis of randomised trials. BMJ 2003; 326: 789.
8. Jacobson S. Human T lymphotropic virus, type-1 myelopathy: an immunopathologically mediated chronic progressive disease of the central nervous system. Curr Opin Neurol 1995; 8: 179-183.
9. Lehkey TJ, Levin MC, Kubota R, et al. Reduction in HTLV-1 proviral load and spontaneous lymphoproliferation in HTLV-1-associated myelopathy/ tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol 1998; 44: 942-947.
10. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA 1999; 96: 7462-7466.
11. Waldmann TA. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssee. J Clin Immunol 2007; 27: 1-18.
12. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β. Proc Natl Acad Sci USA 2004; 101: 8705-8708.
13. Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004; 56: 864-867.
14. Rose JW, Burns JB, Bjorklund J, Klein J, Watts HE, Carlson NG. Daclizumab phase II trial in relapsing and remitting multiple sclerosis. Neurology 2007; 69: 785-789.
15. Montalban X, Wynn D, Kaufmann M, Wang M, Fong A. Preliminary CHOICE results: a phase 2, randomised, placebo-controlled multicentre study of subcutaneous daclizumab in patients with active, relapsing forms of multiple sclerosis on interferon beta (abstract). 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Prague, Czech Republic, 2007.
16. bright natural killer cells mediate immunomodulatory effects of IL-2Ra-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103: 5941-5946.